TNF and inflammatory bowel disease: Infliximab (IFX) is a chimeric monoclonal antibody that targets tumor necrosis factor alpha (TNF-α), a proinflammatory cytokine that plays a key role in the pathogenesis of inflammatory bowel disease (IBD).